Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Arch Dermatol Res.

Florek AG, Wang CJ, Armstrong AW

doi: 10.1007/s00403-018-1808-x.

Psoriasis

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

JAMA Dermatol

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1001/jamadermatol.2020.4202

Psoriasis

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Br J Dermatol.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R

doi: 10.1111/bjd.17149.

PsoriasisPsoriatic ArthritisSpinal Disorders

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Ann Rheum Dis.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T

doi: 10.1136/annrheumdis-2018-214273.

Psoriasis

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

J Eur Acad Dermatol Venereol.

Gerdes S, Pinter A, Papavassilis C, Reinhardt M

doi: 10.1111/jdv.16004.

Psoriasis

The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017

J Am Acad Dermatol.

Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR

doi: 10.1016/j.jaad.2020.04.139.

Psoriasis

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

Lancet

Papp KA, Weinberg MA, Morris A, Reich K

doi: 10.1016/S0140-6736(21)00440-2

Related content

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study